2 recruiting, 1 active not recruiting, 1 enrolling by invitation, 1 not yet recruiting. 2 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Deafness, Autosomal Recessive 9: new trials by email Literature Review of Deafness, Autosomal Recessive 9 trials Research Report on Deafness, Autosomal Recessive 9
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetic Study of OTOF- Related Auditory Neuropathy Spectrum Disorder Whole exome sequencing. - Auditory Neuropathy Spectrum Disorder, Auditory Neuropathy | Not yet recruiting | Sohag University | 30 | 2026-08-01 | 2026-08-21 | |
| A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF), Biallelic Mutations in the Gap Junction Beta 2 (GJB2) Gene | Withdrawn | Regeneron Pharmaceuticals | 2025-06-30 | 2025-05-15 | ||
| Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy Otoferlin Gene-mediated Hearing Loss | Enrolling by invitation | Eli Lilly and Company | 30 | 2024-11-11 | 2026-11-04 | |
| A Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations SENS-501 administration - OTOF Gene Mutation, DFNB9 | Phase 1 / Phase 2 | Active not recruiting | Sensorion | 12 | 2024-06-21 | 2026-07-08 |
| Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss AAVAnc80-hOTOF via Akouos Delivery Device, AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism - Sensorineural Hearing Loss, Bilateral | Phase 3 | Recruiting | Eli Lilly and Company | 48 | 2023-09-15 | 2026-09-29 |
| A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations DB-OTO - Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 36 | 2023-06-27 | 2026-08-05 |
Auditory neuropathy (5) · Hearing Loss (5) · Hearing Loss, Sensorineural (5) · Deafness (3) · Hearing Disorders (3) · Hearing Loss, Bilateral (2) · Ear Diseases (1) · Hearing Loss, Hidden (1) · Otorhinolaryngologic Diseases (1)
Nervous System Diseases (6) · Neurologic Manifestations (6) · Pathological Conditions, Signs and Symptoms (6) · Sensation Disorders (6) · Signs and Symptoms (6) · Ear Diseases (5) · Otorhinolaryngologic Diseases (5) · Hearing Disorders (3) · Hearing Loss (1)
Exome (1) · OTOF protein, human (1)
Eli Lilly and Company (2) · Regeneron Pharmaceuticals (2) · Sensorion (1) · Sohag University (1)
United States (4) · Spain (2) · Taiwan (2) · United Kingdom (2) · Australia (1) · Canada (1) · Egypt (1) · France (1) · Germany (1) · Japan (1)
PMID 41085057, PMID 12809326, PMID 19409623, PMID 22939890, PMID 26818607, PMID 27340636, PMID 27729456, PMID 28696301, PMID 29111973, PMID 29688962, PMID 30482216, PMID 31453354, PMID 33908410, PMID 34424407, PMID 36769387, PMID 37679651, PMID 42279121
2023 (1)